Archives
- 2026-04
- 2026-03
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
- 2021-12
- 2021-11
- 2021-10
- 2021-09
- 2021-08
- 2021-07
- 2021-06
- 2021-05
- 2021-04
- 2021-03
- 2021-02
- 2021-01
- 2020-12
- 2020-11
- 2020-10
- 2020-09
- 2020-08
- 2020-07
- 2020-06
- 2020-05
- 2020-04
- 2020-03
- 2020-02
- 2020-01
- 2019-12
- 2019-11
- 2019-10
- 2019-09
- 2019-08
- 2019-07
- 2019-06
- 2019-05
- 2019-04
- 2018-11
- 2018-10
- 2018-07
-
Eltanexor (KPT-8602): Translating XPO1 Inhibition to Oncolog
2026-04-22
Eltanexor (KPT-8602), a next-generation oral XPO1 inhibitor, is redefining the boundaries of translational oncology by targeting nuclear export mechanisms pivotal to cancer cell survival and progression. This article synthesizes mechanistic insights, recent preclinical findings—including modulation of the Wnt/β-catenin pathway in solid tumors—and strategic considerations for translational researchers. It contrasts Eltanexor’s mechanistic and translational advantages with legacy XPO1 inhibitors, offering practical guidance and evidence-backed recommendations for experimental design, dosage, and workflow integration. By escalating the discussion beyond typical product summaries and connecting the latest research with laboratory implementation, this thought-leadership piece provides actionable direction for researchers aiming to leverage Eltanexor’s unique therapeutic profile in acute myeloid leukemia, chronic lymphocytic leukemia, diffuse large B-cell lymphoma, and colorectal cancer models.
-
HyperScribe™ Poly (A) Tailing Kit: Advancing mRNA Stability
2026-04-22
The HyperScribe™ Poly (A) Tailing Kit empowers researchers to enzymatically generate highly stable, efficiently translated mRNA for advanced transfection and gene expression studies. Its robust protocol, leveraging E. coli Poly (A) Polymerase, delivers precision polyadenylation and straightforward troubleshooting, outperforming traditional methods for in vitro RNA modification.
-
Praeruptorin A Suppresses NF-κB and Inflammatory Genes in Ma
2026-04-21
This study demonstrates that Praeruptorin A, a natural angular pyranocoumarin compound, inhibits NF-κB pathway activation and pro-inflammatory gene expression in poly(I:C)-stimulated RAW264.7 macrophages. The findings highlight its mechanistic potential as an anti-inflammatory agent for virus-related immune responses.
-
Panobinostat Targets Epigenetic Vulnerabilities in MLL-ALL
2026-04-21
This study demonstrates that panobinostat, a histone deacetylase inhibitor, exerts potent in vivo anti-leukaemic effects in models of MLL-rearranged acute lymphoblastic leukaemia (ALL) by disrupting the RNF20/RNF40/WAC-H2B ubiquitination axis. The findings highlight the therapeutic potential of epigenetic modulation in aggressive infant ALL subtypes with poor prognosis, offering mechanistic insight for future research.
-
Tin Mesoporphyrin IX (chloride): Reliable HO Inhibition for
2026-04-20
This article addresses persistent laboratory challenges in cell viability and metabolic research, illustrating how Tin Mesoporphyrin IX (chloride) (SKU C5606) offers reproducible, nanomolar-potency inhibition of heme oxygenase. Drawing on scenario-driven Q&A, published data, and protocol guidance, it demonstrates best practices for integrating this reagent into sensitive workflows.
-
Ziprasidone Augmentation in Escitalopram-Treated Anxious Dep
2026-04-20
This study investigates whether adding ziprasidone to escitalopram enhances outcomes in patients with anxious versus nonanxious depression. The results reveal no significant difference in depressive symptom improvement between groups, and the anxiolytic effects observed were not clinically meaningful, refining expectations for combination strategies in antidepressant research.
-
Deracoxib: Selective COX-2 Inhibitor for Advanced Inflammati
2026-04-19
Harness the unique properties of Deracoxib, a selective COX-2 inhibitor, to enhance the precision and translational relevance of inflammation and cancer biology assays. This article delivers practical workflow strategies, highlights experimental synergies, and offers troubleshooting tips grounded in recent peer-reviewed findings.
-
CCK-8 in Translational Research: Precision for EMT-Driven On
2026-04-18
Explore how the Cell Counting Kit-8 (CCK-8) enables high-resolution insights into cell proliferation and viability, with a mechanistic spotlight on EMT-mediated glioblastoma progression and chemoresistance. This article contextualizes CCK-8’s WST-8 chemistry within the current translational landscape, integrates evidence from recent TMEM165 research, and provides actionable protocol guidance for maximizing assay impact in cancer biology.
-
BMN 673 (Talazoparib): Precision PARP1/2 Inhibition in DNA R
2026-04-17
BMN 673 (Talazoparib) stands out as a next-generation PARP1/2 inhibitor, enabling highly selective targeting of homologous recombination deficient cancers. This article delivers actionable workflows, troubleshooting tips, and translation of the latest mechanistic insights for maximizing experimental success with this tool.
-
Cardiogreen (Indocyanine Green): Mechanisms & Translational
2026-04-16
Explore how Cardiogreen (Indocyanine Green) is revolutionizing vascular diagnostics and photodynamic therapy, with mechanistic depth on apoptosis induction and tumor microenvironment remodeling. Strategic guidance is offered for translational researchers aiming to bridge advanced diagnostics with next-generation immunotherapy.
-
GM 6001 (Galardin): Precision MMP Inhibition for ECM Researc
2026-04-15
GM 6001 (Galardin) empowers researchers to precisely inhibit matrix metalloproteinases (MMPs) in diverse models, from neurodegeneration to tissue repair. Its nanomolar potency and proven efficacy in preserving extracellular matrix integrity set a benchmark for reproducibility and data quality.
-
Photothermal Therapy and CD47 Blockade in OSCC: Synergistic
2026-04-14
This article analyzes a recent study demonstrating how photothermal therapy (PTT) synergizes with CD47 blockade to enhance anti-tumor immunity in oral squamous cell carcinoma (OSCC) by promoting calreticulin exposure and extracellular matrix remodeling. The work establishes a mechanistic rationale for combining immunotherapy with tumor-priming interventions, offering translational insights for researchers interested in immunogenic cell death workflows.
-
Cy5 NHS ester(Et): Technical Guidance for Protein Labeling W
2026-04-13
Cy5 NHS ester(Et) provides a high-purity, amine-reactive fluorescent dye for reproducible protein and biomolecule labeling in immunofluorescence, flow cytometry, and microscopy. It is best suited for workflows requiring water-soluble labeling reagents with robust primary amine reactivity. This product is not intended for applications requiring ethanol solubility or long-term solution storage.
-
QRICH1 Drives HBV-Induced HMGB1 Secretion in Hepatic Fibrosi
2026-04-12
This study reveals that QRICH1 acts as a central effector in endoplasmic reticulum (ER) stress, enhancing hepatitis B virus (HBV)-mediated HMGB1 translocation and secretion in hepatocytes. These findings clarify the mechanistic link between ER stress, QRICH1, and HBV-driven hepatic fibrosis, with implications for future strategies targeting fibrogenic pathways.
-
3-Methyladenine in Autophagy and Cell Migration: Workflow &
2026-04-12
3-Methyladenine (3-MA) is a gold-standard tool for dissecting autophagy pathways and cell migration in cancer and infection models. This article details optimized protocols, troubleshooting guidance, and new insights from recent studies—empowering researchers to maximize reproducibility and biological insight with 3-MA.